TNFRSF13C and atherosclerosis: As a B cell depletion therapeutic strategy for atherosclerosis, anti-BAFFR monoclonal antibody seems therapeutically more specific than anti-CD20 monoclonal antibody treatment as it only depletes atherogenic B2 cells while sparing atheroprotective B1a cells.